[1]杨 昕,刘 芳,杜 静,等.肺癌癌组织中过氧化物酶增殖体激活受体γ基因表达水平对培美曲塞化疗疗效的预测价值*[J].陕西医学杂志,2020,49(10):1359-1362.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
　YANG Xin,LIU Fang,DU Jing,et al.Predictive value of PPARγ gene expression level in lung cancer tissue for curative effect of pemetrexed chemotherapy[J].,2020,49(10):1359-1362.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
点击复制

肺癌癌组织中过氧化物酶增殖体激活受体γ基因表达水平对培美曲塞化疗疗效的预测价值*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年10期
页码:
1359-1362
栏目:
临床病理
出版日期:
2020-10-05

文章信息/Info

Title:
Predictive value of PPARγ gene expression level in lung cancer tissue for curative effect of pemetrexed chemotherapy
作者:
杨 昕1; 刘 芳1; 杜 静1; 张继朋2
1.陕西中医药大学第二附属医院病理科(咸阳 712000); 2.空军军医大学唐都医院胸外科(西安 710038)
Author(s):
YANG Xin; LIU Fang; DU Jing; et al.
Department of Pathology,the Second Affiliated Hospital of Shaanxi University of Chinese Medicine(Xianyang 712000)
关键词:
非小细胞肺癌;  培美曲塞;  化疗;  过氧化物酶增殖体激活受体γ
Keywords:
Non-small cell lung cancer;  Pemetrexed;  Chemotherapy;  Peroxisome proliferator-activated receptor gamma
分类号:
R734.2
DOI:
DOI:10.3969/j.issn.1000-7377.2020.10.042
文献标志码:
A
摘要:
目的:探讨肺癌癌组织中过氧化物酶增殖体激活受体γ(PPARγ)基因表达水平对培美曲塞化疗疗效的预测价值。方法:选取经组织病理学验证为晚期非小细胞肺癌(NSCLC)患者80例为研究对象,qRT-PCR检测化疗前各组患者癌组织及癌旁正常组织中PPARγ基因表达水平,所有患者均进行培美曲塞联合铂类化疗,统计客观缓解率(ORR)及疾病控制率(DCR),利用受试者工作特征曲线(ROC)评价PPARγ基因表达水平对培美曲塞化疗疗效的预测价值,并根据Cutoff值将所有患者分为PPARγ高表达组及PPARγ低表达组,Kaplan-Meier法分析PPARγ水平与患者2年生存率的关系。结果:癌组织中PPARγ基因mRNA表达水平高于癌旁正常组织,比较差异有统计学意义(P<0.05); 化疗后完全缓解0例,部分缓解26例,稳定35例,进展19例,ORR为32.50%,DCR为76.25%,疾病控制组PPARγ mRNA表达水平高于病情进展组,两组比较差异有统计学意义(P<0.05); ROC分析结果显示,PPARγ表达水平预测培美曲塞化疗有效的AUC=0.779,95%CI:0.673～0.885,Cutoff值为2.855; 80例NSCLC患者2年内死亡42例,存活率为47.50%,Kaplan-Meier曲线结果显示PPARγ高表达组的2年总生存率58.82%(30/51)显著高于PPARγ低表达组的27.59%(8/29)。结论:高表达PPARγ基因患者应用培美曲塞化疗的效果要优于低表达PPARγ基因患者。
Abstract:
Objective:To explore the predictive value of peroxisome proliferator-activated receptor gamma(PPARγ)gene expression level in lung cancer tissue for curative effect of pemetrexed chemotherapy.Methods:Eighty patients with advanced non-small cell lung cancer(NSCLC)confirmed by histopathology were enrolled as study objects.The expression level of PPARγ gene in cancer tissue and normal adjacent tissue in each group before chemotherapy was detected by qRT-PCR.All patients underwent pemetrexed combined with platinum chemotherapy.The objective remission rate(ORR)and disease control rate(DCR)were statistically analyzed.The predictive value of PPARγ gene expression level for curative effect of pemetrexed chemotherapy was evaluated by receiver operating characteristic(ROC)curve.According to different cutoff values,all patients were divided into PPARγ high-expression group and PPARγ low-expression group.The relationship between PPARγ level and 2-year survival rate was analyzed by Kaplan-Meier method.Results:The mRNA expression level of PPARγ gene in cancer tissue was higher than that in normal adjacent tissue(P<0.05).After chemotherapy,there were 0 case with complete remission,26 cases with partial remission,35 cases in stable stage and 19 cases in advanced stage.ORR and DCR were 32.50% and 76.25%,respectively.The mRNA expression level of PPARγ gene in disease control group was higher than that in disease progression group(P<0.05).ROC analysis results showed that AUC,95%CI and Cutoff value of PPARγ expression level for predicting the effectiveness of pemetrexed chemotherapy were 0.779,0.673-0.885 and 2.855,respectively.Among the 80 NSCLC patients,there were 42 cases died within 2 years,with survival rate of 47.50%.Kaplan-Meier curve results showed that 2-year overall survival rate in PPARγ high-expression group was significantly higher than that in PPARγ low-expression group [58.82%(30/51)vs.27.59%(8/29)].Conclusion:The effect of pemetrexed chemotherapy in patients with high-expression PPARγ gene are better than that in patients with low-expression PPARγ gene.

参考文献/References:

[1] 王 玲,申 鸿.癌胚抗原、糖类抗原、CA125、血管生成素、细胞角蛋白19片段及甲胎蛋白检测在肺癌诊断中的临床研究[J].陕西医学杂志,2019,48(8):1080-1084.
[2] Shen Y,Wu B,Wang X,et al.Health state utilities in patients with advanced non-small-cell lung cancer in China[J].J Comp Eff Res,2018,7(5):443-452.
[3] 王亚旗,王 兴,阎 石,等.非小细胞肺癌新辅助治疗联合外科治疗的进展[J].中国肺癌杂志,2017,20(5):352-360.
[4] 王 岚,刘宝刚.培美曲塞与顺铂配伍治疗晚期肺腺癌132例疗效与安全性分析[J].陕西医学杂志,2015,44(9):1142-1144.
[5] 徐 飞,乔万海.多器官功能障碍综合征患者外周血单个核细胞内PPARγ和COX-2的关系[J].陕西医学杂志,2018,47(9):1105-1108.
[6] 王丽红,王楠楠,王光明.过氧化物酶体增殖物激活受体在中枢神经系统肿瘤中作用的研究进展[J].广东医学,2016,37(10):1561-1563.
[7] 何建行,钟南山,杨海虹.非小细胞肺癌临床实践指南精确解读[J].中华医学杂志,2008,88(40):2814-2816.
[8] 刘红柳,杨家梅.培美曲塞单药或联合吉非替尼治疗EGFR-TKI耐药后晚期非小细胞肺癌临床观察[J].中国癌症杂志,2017,27(2):135-139.
[9] 袁 征,李 珍,孙彦珍,等.培美曲塞注射剂联合顺铂注射剂治疗非小细胞肺癌的临床疗效研究[J].中国临床药理学杂志,2018,34(7):790-792.
[10] 周 娟,倪松石.EGFR基因突变对晚期肺腺癌患者培美曲塞疗效的影响[J].江苏医药,2015,41(15):1764-1767.
[11] 陈 红,周晓红,陆国权,等.培美曲塞注射剂联合顺铂注射剂治疗复发性肺腺癌的临床研究[J].中国临床药理学杂志,2017,33(12):1079-1081.
[12] 马晶晶,章 涛.PPARγ功能与疾病关系研究进展[J].中国药理学通报,2012,28(5):601-604.
[13] Girnun GD.The diverse role of the PPARγ coactivator 1 family of transcriptional coactivators in cancer[J].Seminars in Cell & Developmental Biology,2012,23(4):381-388.
[14] 李 虹,林 箐,宋琳琳,等.PPARγ在非小细胞肺癌中的表达及其在预后评估中的意义[J].中国现代医学杂志,2012,22(5):35-38.
[15] 李 强,党诚学.PPARγ mRNA在胃癌组织中的表达及其与胃癌预后的关系[J].实用癌症杂志,2012,27(1):18-20.

相似文献/References:

[1]王晓东,景鹏宇△,崔 凯,等.术前外周血中性粒细胞淋巴细胞比值对ⅠⅢ期非小细胞肺癌患者预后的影响[J].陕西医学杂志,2019,(12):1612.
[2]王冠杰,王 鹏△.培美曲塞联合顺铂治疗非小细胞肺癌疗效及对患者细胞角质抗原21-1、磷酸化细胞外信号调节激酶水平的影响研究*[J].陕西医学杂志,2020,49(7):804.[doi:DOI:10.3969/j.issn.10007377.2020.07.009]
　WANG Guanjie,WANG Peng..Therapeutic effect of pemetrexed combined with cisplatin in treatment of non-small cell lung cancer and its influence on CYFRA21-1 and p-ERK levels[J].,2020,49(10):804.[doi:DOI:10.3969/j.issn.10007377.2020.07.009]
[3]彭 峰,彭奕华,张宏华,等.非小细胞肺癌化疗前后血清糖类抗原125、肿瘤异常蛋白水平变化及其与疗效的关系[J].陕西医学杂志,2020,49(7):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
　PENG Feng,PENG Yihua,ZHANG Honghua,et al.Changes of serum CA125 and TAP levels before and after chemotherapy for non-small cell lung cancer and their relationship with curative effect[J].,2020,49(10):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
[4]王晓东,吕 峰△,崔 凯.ⅢA-N2期非小细胞肺癌纵隔淋巴结跳跃性转移临床特点及对预后的影响[J].陕西医学杂志,2020,49(12):1634.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.025]
[5]苏艳丽,李 波.Th9细胞对非小细胞肺癌患者CD8+T细胞抗肿瘤活性的调控作用[J].陕西医学杂志,2021,50(1):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
　SU Yanli,LI Bo.Regulatory of Th9 cells on anti-tumor activity of CD8+T cells in patients with non-small-cell lung cancer[J].,2021,50(10):15.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.004]
[6]岳 英,董锦华,肖月梅.肺免疫微环境中调节因子表达对肿瘤生长和转移的影响[J].陕西医学杂志,2021,50(4):495.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.030]
[7]崔 凯,白峻峰,支亚男,等.外泌体微小RNA-23a对非小细胞肺癌血管生成的影响及机制研究[J].陕西医学杂志,2021,50(9):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
　CUI Kai,BAI Junfeng,ZHI Ya'nan,et al.Effect of exosome miR-23a on angiogenesis in NSCLC and its mechanism[J].,2021,50(10):1048.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.002]
[8]陈 彦,姜立朋.基于CT的影像组学特征对非小细胞肺癌放射治疗效果的评估价值[J].陕西医学杂志,2021,50(9):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
　CHEN Yan,JIANG Lipeng.Evaluation value of CT-based imaging omics features for radiotherapy effect in treatment of non-small cell lung cancer[J].,2021,50(10):1094.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.013]
[9]崔 凯,支亚男,王壮壮,等.微小RNA-30对非小细胞肺癌侵袭、转移能力的影响及机制研究[J].陕西医学杂志,2021,50(10):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
　CUI Kai,ZHI Ya'nan,WANG Zhuangzhuang,et al.Effect and mechanism of miR-30 on invasion and metastasis of non-small cell lung cancer[J].,2021,50(10):1214.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.009]
[10]梁乐乐,王 鹏,刘俊霞,等.非小细胞肺癌组织中T细胞免疫球蛋白区黏蛋白-3、程序性死亡因子-1及程序性因子配体1的表达分析[J].陕西医学杂志,2021,50(10):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]
　LIANG Lele,WANG Peng,LIU Junxia,et al.Expression of TIM-3,PD-1 and PD-L1 in non-small cell lung cancer[J].,2021,50(10):1227.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.012]

备注/Memo

备注/Memo:
*陕西省自然科学基金资助项目(2016JM2-6115)
更新日期/Last Update: 2020-10-10